Terug
Ook genoteerd als
OTSKY
OTC
Dagbereik
€ 69,59
€ 69,59
52-Weeksbereik
€ 44,40
€ 70,34
Volume
212
50D / 200D Gem.
€ 57,93
/
€ 52,15
Vorige Slotkoers
€ 70,34
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 12,6 | 3,7 |
| Net Margin % | 14,7 | 3,8 |
| Rev Growth 5Y % | 13,3 | 10,0 |
| D/E | 0,1 | 0,2 |
Belangrijkste Punten
Revenue grew 13,32% annually over 5 years — strong growth
ROE of 12,60% — decent returns on equity
Debt/Equity of 0,10 — conservative balance sheet
Generating 316,01B in free cash flow
P/E of 0,10 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,26%
Groei
Revenue Growth (5Y)
13,32%
Revenue (1Y)6,06%
Earnings (1Y)5,93%
FCF Growth (3Y)36,92%
Kwaliteit
Return on Equity
12,60%
ROIC9,26%
Net Margin14,71%
Op. Margin16,71%
Veiligheid
Debt / Equity
0,10
Current Ratio2,17
Interest Coverage15,26
Waardering
P/E Ratio
0,10
P/B Ratio0,01
EV/EBITDA-0,46
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,06% | Revenue Growth (3Y) | 10,64% |
| Earnings Growth (1Y) | 5,93% | Earnings Growth (3Y) | 72,88% |
| Revenue Growth (5Y) | 13,32% | Earnings Growth (5Y) | 30,46% |
| Profitability | |||
| Revenue (TTM) | 2,47T | Net Income (TTM) | 363,47B |
| ROE | 12,60% | ROA | 8,65% |
| Gross Margin | 71,68% | Operating Margin | 16,71% |
| Net Margin | 14,71% | Free Cash Flow (TTM) | 316,01B |
| ROIC | 9,26% | FCF Growth (3Y) | 36,92% |
| Safety | |||
| Debt / Equity | 0,10 | Current Ratio | 2,17 |
| Interest Coverage | 15,26 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 0,10 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | 1,52 |
| EV/EBITDA | -0,46 | Dividend Yield | 0,02% |
| Market Cap | 36,75B | Enterprise Value | -191,05B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,47T | 2,33T | 2,02T | 1,74T | 1,50T |
| Net Income | 363,47B | 343,12B | 121,62B | 133,91B | 125,46B |
| EPS (Diluted) | 685,44 | 633,77 | 224,10 | 246,79 | 231,15 |
| Gross Profit | 1,77T | 1,67T | 1,41T | 1,17T | 1,00T |
| Operating Income | 412,79B | 323,56B | 139,61B | 150,32B | 154,50B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 4,20T | 3,74T | 3,36T | 3,10T | 2,82T |
| Total Liabilities | 1,10T | 961,09B | 924,93B | 840,17B | 775,73B |
| Shareholders' Equity | 3,04T | 2,73T | 2,39T | 2,23T | 2,01T |
| Total Debt | 307,31B | 189,38B | 214,19B | 194,16B | 212,45B |
| Cash & Equivalents | 535,11B | 426,17B | 513,34B | 471,63B | 410,68B |
| Current Assets | 1,62T | 1,37T | 1,33T | 1,19T | 1,05T |
| Current Liabilities | 749,77B | 632,66B | 667,23B | 539,19B | 467,91B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026